HIV / AIDS in the News

Highly effective prevention drug arrives in South Africa, which has world's highest HIV burden - Medical Xpress

 

Highly effective prevention drug arrives in South Africa, which has world's highest HIV burden - AP News

 

Will HIV Win and Lung Cancer Loss in Trials Recast Merck’s (MRK) Risk Reward Narrative? - Yahoo Finance

 

'We're not seeing a rebound': New data shows HIV services not recovering - Devex

 

Highly effective prevention drug arrives in South Africa, which has world's highest HIV burden - Toronto Star

 

Highly effective prevention drug arrives in South Africa, which has world's highest HIV burden - AP News

 

Highly effective prevention drug arrives in South Africa, which has world's highest HIV burden - The Killeen Daily Herald

 

Highly effective prevention drug arrives in South Africa, which has world's highest HIV burden - The Independent

 

Highly effective prevention drug arrives in South Africa, which has world's highest HIV burden - Yahoo

 

45 years after first AIDS report, HIV cases are rising again in NYC - Spectrum News NY1

 

Gilead-MSD once-weekly oral HIV regimen meets Phase III endpoints - European Pharmaceutical Review

 

New Long Acting Oral HIV Regimen Meets Primary Endpoints In Phase 3 Trials - NDTV

 

aidsmap: Worse HIV control at diagnosis doesn’t mean worse lymphoma outcomes - European AIDS Treatment Group

 

The Conversation: HIV enters the brain and doesn’t leave – paradoxically, drugs intended to reduce brain inflammation increase virus levels - European AIDS Treatment Group

 

South Africa Rolls Out Game-Changing HIV Shot Amid Funding Shortfalls - nextbillion.net

 

Gilead's lung cancer bid for Trodelvy hits wall, but HIV studies deliver better news - FirstWord Pharma

 

[Press release] Gilead and Merck announce positive topline results from two Phase 3 studies evaluating islatravir/lenacapavir, an oral once-weekly HIV treatment - European AIDS Treatment Group

 

AIDS Memorial Quilt on display as UCSD’s Owen Clinic holds vigil for those lost to HIV - Times of San Diego

 

Defective HIV RNA Linked to Persistent Viremia During Long-Term ART - Genetic Engineering and Biotechnology News

 

A year later, UCSD’s first lung transplant for patient with HIV is called a success - San Diego Union-Tribune

 

Merck, Gilead share positive phase 3 results from combination HIV pill - Seeking Alpha

 

Sudan approves $139 million plan to combat malaria, tuberculosis and HIV - Sudan Tribune

 

Gilead and Merck’s Once-Weekly HIV Combo Pill Works in Trials - Bloomberg

 

Once-Weekly HIV Pill Meets Phase 3 Endpoints, Advancing Potential First Long-Acting Oral Treatment - Contagion Live

 

Once-Weekly HIV Pill Meets Phase 3 Endpoints, Advancing Potential First Long-Acting Oral Treatment - Contagion Live

 

Bangor homeless camp closure disrupted response to HIV outbreak, CDC says - Bangor Daily News

 

Gilead and Merck’s once-weekly HIV pill meets trial goals - Investing.com

 

Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment - Business Wire

 

South Africa : 8.15 million South Africans are living with HIV - Africa24 TV

 

A Clinical Trial to Evaluate an Investigational Medicine for HIV-1 Preexposure Prophylaxis (PrEP) - Black Doctor